Abstract | BACKGROUND & AIMS: METHODS: Adults with advanced hepatocellular carcinoma, measurable disease, and an Eastern Cooperative Oncology Group performance scoreā©½1 were enrolled. Eligible subjects were randomly assigned 1:1:1 to tigatuzumab (6 mg/kg loading, 2 mg/kg/week maintenance) plus sorafenib 400 mg twice daily; tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib 400 mg twice daily; or sorafenib 400 mg twice daily. The primary end point was time to progression. Secondary end points included overall survival and safety. RESULTS: 163 subjects were randomized to treatment. Median time to progression was 3.0 months in the tigatuzumab 6/2 mg/kg combination group (p=0.988 vs. sorafenib), 3.9 months in the tigatuzumab 6/6 mg/kg combination group (p=0.586 vs. sorafenib), and 2.8 months in the sorafenib alone group. Median overall survival was 12.2 months in the tigatuzumab 6/6 mg/kg combination group (p=0.659 vs. sorafenib), vs. 8.2 months in both other treatment groups (p=0.303, tigatuzumab 6/2 mg/kg combination vs. sorafenib). The most common treatment-emergent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, and decreased appetite. CONCLUSIONS:
|
Authors | Ann-Lii Cheng, Yoon-Koo Kang, Aiwu Ruth He, Ho Yeong Lim, Baek-Yeol Ryoo, Chao-Hung Hung, I-Shyan Sheen, Namiki Izumi, TaShara Austin, Qiang Wang, Jonathan Greenberg, Shinichi Shiratori, Robert A Beckman, Masatoshi Kudo, Investigators’ Study Group |
Journal | Journal of hepatology
(J Hepatol)
Vol. 63
Issue 4
Pg. 896-904
(Oct 2015)
ISSN: 1600-0641 [Electronic] Netherlands |
PMID | 26071796
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Phenylurea Compounds
- tigatuzumab
- Niacinamide
- Sorafenib
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Agents
(administration & dosage)
- Carcinoma, Hepatocellular
(drug therapy, pathology)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Liver Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Niacinamide
(administration & dosage, analogs & derivatives)
- Phenylurea Compounds
(administration & dosage)
- Receptors, Vascular Endothelial Growth Factor
- Retrospective Studies
- Sorafenib
- Time Factors
- Treatment Outcome
|